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Abstract
Mutations or amplification of the MET proto-oncogene are involved in the pathogenesis of several 
tumours1-4, which rely on the constitutive engagement of this pathway for their growth and 
survival1,5. However, MET is expressed not only by cancer cells but also by tumour-associated 
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stromal cells although its precise role in this compartment is not well characterized6-11. Here, we 
show that MET is required for neutrophil chemoattraction and cytotoxicity in response to its 
ligand HGF. Met deletion in neutrophils enhances tumour growth and metastasis. This phenotype 
correlates with reduced neutrophil infiltration to both primary tumour and metastatic site. 
Similarly, Met is necessary for neutrophil transudation during colitis, skin rash or peritonitis. 
Mechanistically, Met is induced by tumour-derived TNF-α or other inflammatory stimuli in both 
mouse and human neutrophils. This induction is instrumental for neutrophil transmigration across 
an activated endothelium and iNOS production upon HGF stimulation. Consequently, HGF/MET-
dependent nitric oxide release by neutrophils promotes cancer cell killing, which abates tumour 
growth and metastasis. Following systemic administration of a MET kinase inhibitor, we prove 
that the therapeutic benefit of MET targeting in cancer cells is partly countered by the pro-
tumoural effect rising from MET blockade in neutrophils. Our work identifies an unprecedented 
role of MET in neutrophils, suggests a potential “Achilles’ heel” of MET-targeted therapies in 
cancer, and supports the rationale for evaluating anti-MET drugs in certain inflammatory diseases.
To ensure Met deletion in the immune system only, we took advantage of the Tie2:Cre 
deleter that excises floxed genes in both bone-marrow (BM) and endothelial cells (EC)12 
and we reconstituted lethally irradiated C57BL/6 wild-type (WT) mice with BM cells from 
Tie2;Metwt/wt (WT) or Tie2;Metlox/lox (KO) mice (Extended Data Fig. 2a), producing 
WT→WT or KO→WT mice, respectively. Compared to WT→WT controls, both growth 
and metastatic burden of subcutaneous LLC lung carcinomas were boosted in KO→WT 
mice (Fig. 1a-g), with reduced tumour apoptosis and necrosis, increased proliferation, but 
comparable vessel parameters and hypoxia (Extended Data Fig. 2b-r). A similar induction in 
tumour growth and metastasis was observed in non-irradiated KO versus WT mice 
(Extended Data Fig. 2s-u), but tumour growth, as well as the vascular features, were 
comparable in WT→WT versus WT→KO chimeras, displaying Met deletion in EC only 
(Extended Data Fig. 2o-r,v). Thus, Met deletion in immune cells favours cancer growth and 
metastasis.
Blood counts and percentage of circulating blood cell subsets did not change in WT→WT 
and KO→WT mice, either at baseline or upon LLC tumour engraftment (Extended Data Fig. 
3a-e; Extended Data Table 1,2). Notably, KO→WT mice displayed reduced numbers of 
tumour-infiltrating CD45+ leukocytes and, among all the different subpopulations, only 
Ly6G+ tumour-associated neutrophils (TANs) were strongly reduced in KO→WT versus 
WT→WT mice at any time point (Fig. 1f-j; Extended Data Fig. 3f-k). Similarly, lungs from 
KO→WT tumour-bearing mice contained fewer CD45+ leukocytes with decreased Ly6G+ 
neutrophil infiltration, while macrophages were comparable (Fig. 1k-m; Extended Data Fig. 
3l,m). Furthermore, reconstitution of Met in neutrophils only13 (Extended Data Fig. 4a,b), 
was sufficient to rescue their recruitment and to hinder tumour growth and metastasis in 
KO→WT mice (Fig. 1n-q). Vice versa, restricted deletion of Met in neutrophils 
(Mrp8;Metlox/lox) by the neutrophil-specific Mrp8:Cre line13 (Extended Data Fig. 4c,d) led 
to enhanced tumour growth and dissemination, and marked TAN reduction, as in KO→WT 
chimeras (Fig. 1r-u; Extended Data Fig. 4e). These results indicate that MET is required for 
recruiting anti-tumoural neutrophils.
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To extend our findings to other tumour types, we proved that Met deletion in the 
hematopoietic system increased the growth of i) orthotopic T241 fibrosarcomas and B16F10 
melanomas, ii) spontaneous mammary tumours in MMTV-PyMT+ transgenic mice, iii) H-
RasG12V and c-Myc-driven hepatocellular carcinomas (HCC), and iv) chemically induced 
colorectal cancers (CRC) (Fig. 2a-j; Extended Data Fig. 5a,b). Furthermore, lung 
colonisation of B16F10 melanoma cells (from either the primary tumour or after cancer cell 
intravenous injection) and of MMTV-PyMT+ breast tumours was boosted in Met KO 
chimeras (Fig. 2k,l; Extended Data 5c). In all these tumour types, Met KO TANs were fewer 
than WT TANs (Fig. 2m; Extended Data 5d,e). Interestingly, during chronic bowel 
inflammation (preceding CRC formation), neutrophil but not macrophage infiltration of the 
colon was also abated by hematopoietic Met deletion, but this reduction did not impinge on 
colitis severity (Extended Data 5f-i). B16F10 and HCC displayed enhanced tumour growth 
(and metastasization) as well as reduced TAN infiltration in Mrp8;Metlox/lox versus 
Mrp8;Metwt/wt mice (Fig. 2n-q). Conversely, orthotopic Panc02 carcinomas grew and 
metastasized similarly in both WT→WT and KO→WT mice, and TAN infiltration did not 
change (Extended Data Fig. 5j-l). However, these tumours produced little HGF compared to 
LLC tumours (Extended Data Fig. 5m,n). In general, plasma and intratumour HGF did not 
differ between genotypes (Extended Data Fig. 5o,p). In sum, Met deficiency in neutrophils 
promotes the progression of different (HGF-secreting) tumours.
Systemic treatment of WT mice carrying B16F10 melanomas (which are dependent on 
MET14) with three different MET tyrosine-kinase inhibitors (PF-04217903, INCB28060, 
JNJ-38877605), strongly reduced TAN recruitment (Extended Data Fig. 5q). We then 
compared MET silencing in cancer cells versus systemic MET inhibition. PF-04217903 
decreased weight and volume of B16F10 melanomas by 36% and 54% respectively, whereas 
MET knockdown in cancer cells by 58% and 75% (Fig. 2r,s; Extended Data Fig. 5r). 
However, combination of these two strategies was not synergic but dampened tumour 
inhibition to the same level as observed with PF-04217903 alone (Fig. 2r,s). TAN inhibition 
by PF-04217903 was comparable in both Met-silenced and scramble B16F10 melanomas 
(Fig. 2t). These data unveil how the therapeutic benefit of systemic MET inhibition is partly 
blunted by the blockade of anti-tumoural neutrophils.
To date, MET expression in neutrophils has been poorly documented11. We thus measured 
MET levels in circulating or tumour-infiltrating neutrophils. Circulating Ly6G+ cells from 
healthy mice expressed low MET, but these levels were increased in circulating neutrophils 
from LLC tumour-bearing mice and even further in TANs (Fig. 3a,b; Extended Data Fig. 
6a). Similarly, neutrophils isolated from non-small cell lung tumours displayed much higher 
MET levels than in the healthy tissue (Fig. 3c).
Co-culture with IL-1α pre-activated endothelium as well as stimulation with tumour- or 
cancer cell-conditioned medium (TCM or CCM, respectively) promoted MET expression in 
both mouse and human neutrophils (Fig. 3d-g). In a biased approach15-17, we found that 
TNF-α and LPS (but not IL-1α HGF, or hypoxia) induced MET expression in both mouse 
and human neutrophils (Fig. 3h; Extended Data Fig. 6b-e; not shown). TNF-α-mediated 
MET induction required TNFR1 and subsequent NF-κB activation (Fig. 3i-k). TNF-α alone 
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was not able to trigger either MET phosphorylation or HGF release in neutrophils (Extended 
Data Fig. 6f-h).
Silencing of EC-borne TNF-α (which is 250-fold increased upon stimulation with IL-1α; 
Extended Data Fig. 6i), knockout of neutrophil-borne TNFR1 (but not of TNFR2), 
pharmacological blockade of TNF-α with the TNF-α-trap Enbrel, prevented MET induction 
in mouse or human neutrophils upon co-culture with activated EC or exposure to 
TCM/CCM (Fig. 3l; Extended Data Fig. 6j-m). Finally, systemic administration of Enbrel in 
LLC tumour-bearing mice diminished MET expression in neutrophils as well, resulting in 
their reduced recruitment to the tumour (Fig. 3m,n). Though MET is scarcely expressed in 
naive neutrophils, it is strongly induced by inflammatory stimuli.
Mechanistically, impaired TAN accumulation after Met inactivation was not due to cell 
death as assessed in LLC tumours and in culture, both at baseline and under LPS 
stimulation, with or without HGF (Extended Data Fig. 7a-e), but rather to a defect in 
neutrophil recruitment from the blood. Indeed, in case of acute inflammation, Met KO 
neutrophils displayed reduced exudation to the skin or to the peritoneal cavity (Fig. 4a-d; 
Extended Data Fig. 8a,b). Macrophage or lymphocyte recruitment did not change (Fig. 4d; 
Extended Data Fig. 8c,d). Vice versa, recombinant HGF recruited WT neutrophils inside 
subcutaneous air pouches with similar efficacy than the neutrophil chemoattractant CXCL1 
(Fig. 4e; Extended Data Fig. 8e). Instead, Met KO neutrophils did not migrate towards HGF, 
whilst their response to CXCL1 was preserved (Fig. 4e; Extended Data Fig. 8e). Mirroring 
this approach, an anti-HGF blocking antibody18 prevented neutrophil infiltration to tumours 
and inflamed skin (Fig. 4f).
We then tested the relevance of MET for neutrophil migration. Stimulation of WT 
neutrophils with HGF promoted their adhesion and chemotaxis through an activated 
endothelium whereas Met KO neutrophils (displaying 85% reduction in MET protein levels 
compared to WT; Extended Data Fig. 2a) completely lost this response (Fig. 4g,h; Extended 
Data Fig. 8f). In line with this, TCM (containing 2.6 ± 0.3 ng/ml HGF) promoted 
transendothelial migration of WT neutrophils, but its effect was 43% lower on Met KO 
neutrophils (Fig. 4i). Upon HGF neutralization, WT neutrophils responded to the TCM as 
Met KO neutrophils (Fig. 4i). HGF or TCM did not influence neutrophil behaviour on non-
activated EC or bare membranes (Extended Data Fig. 8f-h). Hence, HGF-mediated MET 
activation is required for neutrophil transendothelial migration to the inflammatory site.
Once migrated inside the tumour, N1 or N2 neutrophils can respectively inhibit or favour 
tumour progression19. Amongst the N1 and N2 genes, only the expression of the N1-marker 
inducible nitric oxide synthase (Nos2, otherwise iNos) was lower in Met KO versus WT 
TANs but similar in macrophages (Fig. 4j; Extended Data Fig. 8i). Compared to WT→WT 
mice, tumours harvested from KO→WT mice displayed reduced nitric oxide (NO) 
production and 3-nitrotyrosine (3NT) formation, a sign of NO-mediated cell damage (Fig. 
4k-n). In vitro, Met KO TANs had lower cancer-cell-killing capacity than WT TANs; iNOS 
inhibition by L-NMMA blunted this difference (Fig. 4o; Extended Data Fig. 8j). HGF-
stimulated WT but not Met KO neutrophils displayed enhanced NO release and cytotoxicity, 
which was abated by L-NMMA (Extended Data Fig. 8k,l).
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We then hypothesized that HGF/MET pathway is key for anti-tumoural neutrophils only. 
Neutrophil depletion in WT→WT chimeras did not affect LLC tumour growth, implying 
that in this tumour model anti-tumoural and pro-tumoural neutrophils are in balance (Fig. 
4p-r). The same treatment in KO→WT mice reduced tumour growth by 34% (Fig. 4p-r), 
indicating that Met deletion inhibits recruitment and activation of cytotoxic, but not of pro-
tumoural neutrophils, which are instead blocked by the anti-Ly6G antibody (Fig. 4r; 
Extended Data Fig. 8m).
In sum, we demonstrate that MET is induced by inflammatory stimuli. This receptor is then 
required for neutrophil extravasation to inflamed tissues. Extravasated neutrophils respond 
to HGF by producing cytotoxic nitric oxide (Extended Data Fig. 1). All these steps restrain 
non-specific immune reactions to the inflammatory site, preventing damage of healthy 
organs.
These findings highlight a double-edged role of MET in cancer: on one side, in MET-
addicted tumours, this pathway is vital for cell-cycle and survival2; on the other side, it 
promotes anti-tumourigenic activities in neutrophils. Thus, alternative approaches targeting 
MET on cancer cells only, and trials guided by new patient selection strategies will be 
important to maximize efficacy of MET inhibition in oncological diseases3,4,20.
Finally, given the fact that MET-inhibiting drugs are not associated to overt toxicity1, MET-
targeted therapies might ameliorate the symptoms of inflammatory disorders wherein 
neutrophils are important for disease pathogenesis21.
METHODS
Animals
The Met floxed mice, a gift of Dr. Snorri S. Thorgeirsson (Center for Cancer Research, NCI, 
Bethesda, MD), were backcrossed in a C57BL/6 background. The Tie2:Cre and MMTV-
PyMT transgenic lines were obtained from our mouse facility. The Mrp8:Cre mice were a 
gift of Dr. Clifford A. Lowell (UCSF, San Francisco, CA) and Dr. Pierre Bruhns (Pasteur 
Institute, Paris, FR)13,22-26. C57BL/6 mice were purchased from Harlan. TNFR1 KO mice 
and TNFR2 KO mice were a gift of Dr. Claude Libert (VIB, Ghent, BE). The Met floxed 
mice were intercrossed for at least two generations with Tie2:Cre or Mrp8:Cre in order to 
obtain Metlox/lox Cre negative (WT) or Metlox/lox Cre positive (KO) littermates for the 
specific promoter. All the experimental procedures were approved by the Institutional 
Animal Care and Research Advisory Committee of the KU Leuven. In all the experiments, 
mice were gender and age matched (within an age range between 6 and 10 weeks).
Cell lines
Murine Lewis lung carcinoma cells (LLC), melanoma B16F10, and human non-small cell 
lung carcinoma A549 cells were obtained from American Type Culture Collection (ATCC); 
the murine pancreatic tumour cell line Panc02 and the murine fibrosarcoma cell line T241 
were respectively a gift from Dr. Cavallaro (IEO, Milano, IT) and Dr. Claesson-Welsh 
(Rudbeck Laboratory, Uppsala, SE). LLC, B16F10, A549, and T241 cells were cultured in 
DMEM (Gibco) supplemented with 2 mM glutamine, 100 units/ml penicillin, 100 μg/ml 
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streptomycin and containing 10% FBS (DMEM 10% FBS). Panc02 cells were cultured in 
RPMI (Gibco) supplemented with 2 mM glutamine, 100 units/ml penicillin, 100 μg/ml 
streptomycin and containing 10% FBS. All these murine tumour cell lines are syngeneic in a 
C57BL/6 background, allowing implantation in Met conditional knockout mice or chimeras. 
Human Umbilical Vein Endothelial Cells (HUVEC) were isolated from human umbilical 
cords and maintained in M199 (Invitrogen) supplemented with 20% FBS, 2 mM glutamine, 
100 units/ml penicillin, 100 μg/ml streptomycin, 0.15% Heparin, 20 μg/ml ECGS (M199 
complete). 0.1% pork gelatin was used to favour the adhesion of HUVEC to the flask 
bottom. All cells were maintained in a humidified incubator in 5% CO2 and 95% air at 
37°C. Three or four different short hairpin RNA lentiviral vectors (Sigma) were used to 
silence Met in LLC, B16F10 or T241 (LLC shMet, B16F10 shMet or T241 shMet; see 
below), or to silence TNFA in HUVEC (HUVEC shTNFA). Scramble lentiviral vectors were 
used as control. Transduced cells were selected with 8 μg/ml puromycin. All cancer cell 
lines and primary HUVEC underwent mycoplasma testing before their use. Negative 
mycoplasma contamination status was verified using LookOut Mycoplasma PCR Kit 
(Sigma) and MycoAlert Mycoplasma Detection Kit plus Assay Control (Lonza). Panc02 and 
T241 cells were both authenticated by Idexx Bioresearch. All cells were passaged in the 
laboratory for no longer than 6 months after receipt. Supplementary Table 1 lists the 
sequences of all the shRNA constructs used in this study.
Bone marrow transplantation and blood cell count
Recipient 6-week old female mice were lethally irradiated (9.5 Gy) and then intravenously 
injected with 107 bone marrow (BM) cells from WT or KO mice 16 hours later. 
Experiments were initiated 5 weeks after BM reconstitution. Blood cell count was 
determined using a hemocytometer on peripheral blood collected by retro-orbital bleeding.
Hematopoietic stem/progenitor cell (HSPCs) transduction
For MET overexpression or reconstitution in respectively WT or Met KO neutrophils, 
lineage negative HSPCs were enriched with the mouse hematopoietic progenitor enrichment 
kit (Stem cell technologies) and checked for purity by FACS according to the 
manufacturer’s protocol. 1×106 cells/ml were pre-stimulated for 5 hours with stem span 
serum-free medium (Stem Cell Technologies) supplemented with IL-3 (20 ng/ml), SCF (100 
ng/ml) TPO (100 ng/ml) and FLT-3L (100 ng/ml) (Promega) and transduced with 1×108 
TU/ml of a lentiviral vector expressing mouse Met under the promoter of the human gene 
S100A8 (Mrp8:Met), which has been engineered for neutrophil-specific transcriptional 
targeting, or an empty vector (Mrp8:Empty) as control. Briefly, the promoter driving Met 
expression in neutrophils only, corresponds to a 3.6 Kb DNA fragment encompassing the 
natural 5′ and 3′ regulatory regions but deleted of its exon coding sequences. Hence, Met is 
under the control of the 5′ and 3′ untraslated regions of the human S100A8 gene and other 
proximal cis regulatory sequences present in the surrogate DNA fragment13,22-26 . Ten hours 
after the first viral transduction, cells received a second round of their respective lentiviral 
vector; 7 hours later 1×106 cells were injected via tail vein in lethally irradiated C57BL/6 
recipient mice. A fraction of transduced HSPCs were cultured and collected after 9 days to 
measure the number of integrated vector copies/cell genome (vector copy number, VCN) by 
qPCR using custom TaqMan assays specific for HIV-gag sequences (Applied Biosystems), 
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as previously described27. Standard curves for HIV-gag (contained by both Mrp8:Empty and 
Mrp8:Met lentiviral vectors) were obtained from the corresponding plasmids. Fifty ng of 
genomic DNA from each sample was subjected to qPCR in quadruplicate using an ABI 
Prism 7500 Fast Real-Time PCR System (Applied Biosystems). VCN was determined 
comparing the amplification signal on the genomic DNA with the standard curve consisting 
of serial dilutions over a 6 log range (slope ≈ −3.3, intercept ≈ 35, efficiency % ≈ 100). 
Average copies per cell genome were calculated taking into account that one murine diploid 
genome = 5.92 pg. The results of this analysis are shown in Supplementary Table 2.
Tumour models
2×106 LLC or 1×106 B16F10 were injected subcutaneously while 2×106 T241 cells were 
injected intradermally in a volume of 200 μl PBS. Tumour volumes were measured 3 times a 
week with a calliper. At endstage, tumours were weighed and collected for histological 
examination or FACS analysis. MMTV-PyMT+ spontaneous breast tumours were measured 
10 weeks after birth (6 weeks after BM transplantation), three times a week, and sacrificed 
at week 16. Lung metastases were contrasted by intratracheal injection of a 15% India ink 
solution, by hematoxylin eosin (H&E) staining on lung paraffin sections, or detected by 
qRT-PCR for the melanoma-specific gene S100B in the models involving B16F10 cells. For 
orthotopic pancreatic tumour growth, mice were anesthetized with isoflurane, the stomach 
exteriorized via abdominal midline incision, and 1×106 Panc02 tumour cells in 30 μl PBS 
were injected into the head of the pancreas using a 29-gauge needle. A successful 
intrapancreatic injection of tumour cells was identified by the appearance of a fluid bleb 
without intraperitoneal leakage. Mice displaying peritoneal leakage were immediately 
sacrificed and excluded from the analysis. At day 12, primary tumours were removed and 
weighed. Enlarged lymph nodes were counted under a stereoscopic microscope. For the 
chemically-induced colorectal cancer model, body-weight-matched mice received one 
intraperitoneal injection of 10 mg/kg of azoxymethane (AOM) followed by 3 cycles of 7 
days of 1.5% (cycle I) or 1.7% (cycle II-III) dextran sodium sulphate (DSS) in drinking 
water, starting from the day of AOM injection28. After 160 days, the colon was collected 
and prepared for histological evaluation with the “Swiss roll” technique29. For the 
oncogene-driven hepatocellular carcinoma model, mice received a 1:1 molar ratio (3 μg total 
DNA) of piggyBac transposons encoding for c-Myc and H-RasG12V oncogenes, driven by 
the PGK promoter, together with the hyperactive piggyBac transposase-encoding plasmid30. 
DNA solutions containing transposon/transposase plasmids were diluted in 2 ml of Ringer’s 
solution and hydrodynamically delivered in 7 seconds through the tail vein.
Lung colonisation assay
In the experimental metastasis assays, 0.5 × 106 B16F10 cells were injected in the tail vein 
and lungs were collected after 12 days. To quantify pulmonary seeding, lungs were 
homogenized in Trizol (Ambion) and RNA was purified with the RNeasy Mini kit (Ambion) 
according to manufacturer’s instructions. The expression of the melanocyte specific gene 
S100B was measured as readout of lung colonization by qRT-PCR following reverse 
transcription to cDNA with the QuantiTect Reverse Transcription kit (Qiagen).
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Mice treatments
To induce chronic colitis, mice received 3 cycles of 7 days of 1.5% (cycle I) or 1.7% (cycle 
II-III) dextran sodium sulphate (DSS) in drinking water; 2 weeks after the last DSS cycle, 
the colon was collected and prepared for histological evaluation as described above29. For in 
vivo MET inhibition, B16F10 tumour-bearing mice received 40 mg/kg PF-04217903 
(AbMole Bioscience) or the corresponding vehicle (0.5% methylcellulose in saline) via oral 
gavage every day once a day starting from day 2 after tumour injection and twice a day from 
day 11 until the end of the experiment; alternatively mice were treated with 50 mg/kg 
INCB28060 (AbMole Bioscience) or 50 mg/kg JNJ-38877605 (Selleckchem). For TNF-α 
inhibition in vivo, LLC tumour-bearing mice were randomized for comparable tumour 
volumes at the endstage and i.p. injected with 10 mg/kg of Enbrel or human IgG in PBS, 
three and one day before tumour collection. For HGF inhibition in vivo, LLC tumour-
bearing mice were randomized when average tumour volume was 300 mm3 and i.p. injected 
with 0.2 mg/mouse of anti-HGF blocking antibody (AF-2207, R&D18,31) or goat IgG in 
PBS. Tumours were collected 20 hours later for histological analysis; TPA ear painting was 
done 5 hours after antibodies administration and ears were collected 15 hours later. For 
neutrophil depletion, mice were treated with 50 μg/20 g body weight of rat anti-mouse Ly6G 
antibody (clone 1A8, BioXCell) or rat IgG every second day starting from day 4 after LLC 
tumour injection and every day from day 12 after tumour injection until the end of the 
experiment. Efficiency of neutrophil depletion was assessed by FACS in blood and tumours.
TPA model of acute skin inflammation
Phorbol ester TPA was used to induce acute skin inflammation as described before32. 
Briefly, TPA (2.5 μg in 20 μl acetone per mouse) was topically applied on the ear skin of 
anaesthetized mice. The contralateral ear was painted with acetone alone as vehicle control. 
Mice were sacrificed after 24 hours and ears collected in 2% PFA for histological analysis.
Zymosan-mediated acute peritonitis model
To induce acute peritonitis, zymosan A (Sigma) was prepared at 2 mg/ml in sterile PBS. 
Four hours after i.p. injection of 0.1 mg zymosan A per mouse, inflammatory exudates were 
harvested by peritoneal lavage with 2 ml PBS. Cells were counted with a Burker chamber 
and stained for Ly6G (1A8) and F4/80 (BM8) for FACS analysis.
Air pouch assay
To create subcutaneous air pouches, BM transplanted chimeric mice or Mrp8;Metlox/lox or 
Mrp8;Metwt/wt mice were injected with 3 ml of sterile air by dorsal subcutaneous injection 
with a butterfly 23G needle on day 0 and on day 3. On day 6, 200 ng/mouse of murine 
CXCL1 or HGF dissolved in 0.5 ml PBS-Heparin (15 U/ml) or PBS-Heparin (15 U/ml) as 
control, were injected in the newly formed dorsal camera. After 4 hours, inflammatory cells 
were harvested by washing the pouch with 5 ml of PBS. Cells were stained for Ly6G (1A8), 
washed and resuspended in PBS 0.1% BSA with unlabelled counting beads and quantified 
by FACS.
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Mouse white blood cell (WBC) isolation
Blood was collected from the retro-orbital vein in 10% heparin. For the isolation of WBC, 
the blood was diluted in 1.25% dextran in saline to allow the sedimentation of red blood 
cells (RBC). After 30′, the supernatant was collected and washed in PBS 0.1% BSA. The 
remaining RBC were lysed in a hypotonic solution of 0.2% NaCl for 30 seconds and 
brought in isotonic condition with 1.6% NaCl and 0.1% glucose. WBC were washed in PBS 
0.1% BSA, counted and resuspended accordingly with the experimental setting.
Mouse blood neutrophil isolation
Blood was collected from the retro-orbital vein in 10% heparin and diluted in an equal 
volume of PBS 0.5% BSA. Up to 5 ml of diluted blood was layered on top of a 
discontinuous gradient of Histopaque 1119 (4 ml) and Histopaque 1077 (5 ml) from Sigma. 
The gradient was centrifuged for 30 minutes at 700g with brake off. The neutrophil layer 
between the Histopaque 1077 and 1119 was collected and washed in PBS 0.5% BSA. RBC 
lysis was performed as above. Neutrophils were washed in PBS 0.5% BSA, counted and 
resuspended according to the experimental condition. Alternatively, blood was sedimented 
in a saline solution containing 1.25% dextran and neutrophils were negatively selected with 
magnetic beads33. Neutrophil purity, as assessed by the hemocytometer, was always higher 
than 93%.
Bone marrow neutrophil and mononuclear cell isolation
In order to reach reasonable amounts of protein, all the Western Blot analyses in mice were 
performed on neutrophils isolated from bone marrows. Mice were sacrificed by cervical 
dislocation. Femurs and tibias were collected in cold sterile Hank Balanced Salt Solution 
(HBSS, Invitrogen) and flushed with HBSS 0.25% BSA. Cells were layered on top of a 
discontinuous gradient of Percoll 81%, 62%, 55%, freshly prepared and centrifuged for 30 
minutes at 2000 g with break off. Monocytes were collected at the interface between the BM 
cells and the layer of Percoll 55%, whereas neutrophils were collected at the interface 
between Percoll 55% and 62%. Cells were washed in HBSS 0.25% BSA and RBC lysis was 
performed as described above. Neutrophils (or monocytes) were washed again, counted and 
resuspended according to the experimental setting. Neutrophil (or monocyte) purity assessed 
by hemocytometer was higher than 87%.
FACS analysis and flow sorting of blood or tumour-associated cells
Blood was collected in 10% heparin and stained for 20 minutes at room temperature. After 
RBC lysis, cells were washed and resuspended in FACS buffer (PBS containing 2% FBS 
and 2 mM EDTA). Tumours were minced in RPMI medium containing 0.1% collagenase 
type I and 0.2% dispase type I (Gibco) for 30 minutes at 37°C and passed through a 70 and 
40 μm cell strainer. After RBC lysis, cells were resuspended in FACS buffer and stained for 
20 minutes at 4°C. Lungs were collected after 7 minutes of transcardial perfusion with saline 
and processed as for the tumours. Briefly, blood or single cell suspensions were incubated 
for 15 minutes at 4°C with Mouse BD Fc Block (2.4G2, BD Pharmingen) 1:100 in FACS 
buffer. The antibodies were added directly in the blocking solution in the appropriate 
combinations (as indicated in the figure legends). CD45 (30F-11), CD11b (M1/70), Ly6G 
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(1A8), CD45R (RA3-6B2), CD3 (17A2), CD4 (RM4-5), IgE (R35-72), CD49b (DX5), 
Ly6C (AL-21) (all from BD Pharmingen), F4/80 (BM8), CD115 (AF598), MHCII 
(M5/114.15-12) (all from eBioscience), were used 1:200 for 2×106 in 100 μl; Siglec-F 
(E50-2440, BD Pharmingen) was diluted 1:750. In all the stainings 7AAD (BD Pharmingen) 
was used to gate out dead cells. For intra-tumour proliferation, 1 mg of BrdU was i.p. 
injected in each mouse 4 hours before tumour collection and cell proliferation was 
quantified on single cell suspensions with the FITC BrdU Flow Kit (BD Bioscience) 
according to manufacturer’s protocol. Tumour apoptosis was assessed by staining single cell 
suspension for the apoptotic marker AnnexinV (1:40, BD Bioscience), excluding 7AAD 
positive cells. For TAN apoptosis, tumour single cell suspensions were gated for CD11b 
(M1/70) and Ly6G (1A8); AnnexinV and 7ADD were used to distinguish apoptotic or dead 
neutrophils. In vitro neutrophil apoptosis was performed by seeding neutrophils isolated 
from tumour-bearing mice at a concentration of 1×106/ml and stimulating them with or 
without LPS (1μg/ml), alone or in combination with HGF (100 ng/ml) for 10 h at 37°C. 
Cells were collected, washed and stained for AnnexinV and 7AAD. The combination of 
CD11b (M1/70), Ly6G (1A8) and MET (eBioclone 7, eBioscience) was used to identified 
triple-positive MET expressing neutrophils in blood or tumour cells 7AAD-negative. 
Freshly stained samples were analysed by FACS Canto II (BD Bioscience). For tumour-
associated neutrophil sorting, myeloid population was enriched by coating with CD11b-
conjugated magnetic beads (MACS, Miltenyi Biotec) and separation through magnetic 
columns (MACS, Miltenyi Biotec), staining with Ly6G and sorting with a FACS Aria I (BD 
Bioscience). Cells were collected in RLT buffer (Qiagen) for RNA extraction or 
resuspended according to the experimental conditions.
Human neutrophil isolation
10 ml of venous blood from healthy volunteers were collected in citrate-coated tubes and 
isolated by erythrocyte sedimentation with dextran and purification with a discontinuous 
plasma-Percoll gradient as already described34.
Lung cancer patients
We enrolled 4 non-small cell lung carcinoma-patients with no previous history of 
oncological, chronic inflammatory, or autoimmune diseases within 10 years prior to this 
study. This patient list includes 2 males (61 and 71 years of age) and 2 females (64 and 68 
years of age), of which 3 smokers (1 T1N0M0 adenocarcinoma, 1 T2N0M0 large cell 
carcinoma, 1 T3N0M0 squamous cell carcinoma) and 1 non-smoker (T2N0M0 
adenocarcinoma). The protocol was approved by the Ethics Committee of the University 
Hospitals Gasthuisberg (Leuven), and all subjects consented prior to study participation.
Flow sorting of neutrophils from lung cancer patients
Lung tumour biopsies or healthy tissues were minced in RPMI medium containing 0.1% 
collagenase type I, 0.2% dispase type I and DNase I 100 U/ml (60 minutes at 37°C), passed 
through a 19 G needle and passed through a 70 and 40 μm cell strainer. After RBC lysis, 
cells were resuspended in FACS buffer (PBS containing 2% FBS and 2 mM EDTA) and 
counted. Myeloid population, enriched using CD11b-conjugated magnetic beads (MACS, 
Miltenyi Biotec) and separated through magnetic column (MACS, Miltenyi Biotec), was 
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stained with anti-CD66b (G10F5, BD Pharmingen) for 20 minutes on ice and sorted with 
FACS Aria I (BD Bioscience). Cells were counted and resuspended in RLT buffer (Qiagen) 
for RNA extraction.
Endothelial cell isolation
Lungs were collected and a single cell suspension was obtained as above. Endothelial cells 
were obtained by performing a negative selection for CD45 (30F-11) and F4/80 (CI:A3-1) 
followed by a positive selection for CD31 (MEC 13.3) by using magnetic beads 
(Dynabeads, Invitrogen) according to the manufacturer’s protocol.
Peritoneal macrophages
5 ml of sterile PBS were injected in the peritoneum of anesthetized mice and collected after 
3 minutes. Cells were centrifuged, washed and culture overnight.
Tumour-conditioned medium (TCM) and LLC (or A549)-conditioned medium (CCM) 
preparation
Two grams of endstage LLC tumour explanted from WT mice were chopped and incubated 
at 37°C in 7 ml of DMEM (supplemented with 2 mM glutamine, 100 units/ml penicillin/100 
μg/ml streptomycin) FBS-free (DMEM 0% FBS). 5×104 LLC (or A549) were seeded in a 6-
multiwell plate in DMEM 10% FBS and incubated at 37°C. Medium alone (DMEM 0% 
FBS or DMEM 10% FBS, respectively) was used to prepare mock controls. After 72 hours, 
the medium was filtered, supplemented with 2 mM glutamine and 20 mM HEPES and 
stored at −20°C. TCM and mock medium (DMEM 0% FBS) were diluted 1:5 in DMEM 
10% FBS; CCM and mock medium (DMEM 10% FBS) were diluted 4:5 in DMEM FBS-
free.
Quantitative RT-PCR (qRT-PCR)
For mRNA analysis, 1×105 or 3×105 mouse or human blood neutrophils, respectively, were 
incubated in normoxic (21% oxygen) or hypoxic (1% oxygen) conditions, or stimulated with 
TCM (plus 50 μg/ml Enbrel or human IgG when indicated), CCM, A549-CCM, 100 ng/ml 
of murine or human TNF-α, 50 ng/ml LPS, or mock medium in 96-multiwell for 4 hours at 
37°C. For NF-κB inhibition, 0.18×106 neutrophils were pre-treated with 10 μM 6-amino-4-
(4-phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 hour at 37°C and stimulated 
with 100 ng/ml of murine TNF-α for 1 hours at 37°C. 2×105 HUVEC were seeded in 24-
multiwell coated with 0.1% gelatin and stimulated with 5 ng/ml IL-1α in DMEM 10% FBS 
for 4 hours at 37°C. Cells were washed in PBS, collected in RLT buffer (Qiagen) and kept at 
−80°C. RNA was extracted with the RNeasy Micro kit (Qiagen) according to 
manufacturer’s instructions. Reverse transcription to cDNA was performed with the 
SuperScript® III First Strand cDNA Synthesis Kit (Life Technologies) according to 
manufacturer’s protocol. Pre-made assays were purchased from Applied Biosystem, except 
for Nos2 that was provided by IDT. cDNA, primer/probe mix and TaqMan Fast Universal 
PCR Master Mix were prepared in a volume of 10 μl according to manufacturer’s 
instructions (Applied Biosystems). Samples were loaded into an optical 96-well Fast 
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Thermal Cycling plate (Applied Biosystems) and qRT-PCR were performed using an ABI 
Prism 7500 Fast Real-Time PCR System (Applied Biosystems)
ELISA
To quantify plasma, intra-tumoural, tumour-released (TCM) and neutrophil-released HGF, a 
murine HGF ELISA kit (R&D) was used according to manufacturer’s protocols. Blood was 
collected from tumour free or tumour bearing mice and plasma was prepared according to 
manufacturer’s instruction. TCM was prepared as above. Tumour proteins were extracted in 
Extraction Buffer (20M Tris HCl, 150mM NaCl, 1% Triton X-100, 10% glycerol, 5 mM 
EDTA). 0.2×106 neutrophils were cultured for 20 hours in DMEM complete in presence or 
absence of 100 ng/ml of murine TNF-α. Medium was collected, spun down and supernatant 
stored at −80°C until use. Mock medium was used as negative control. For phospho-MET 
quantification, 6×106 mouse blood neutrophils isolated from tumour bearing mice were 
cultured in presence or absence of 100 ng/ml of murine TNF-α; 11 hours later, cells were 
stimulated or not with 100 ng/ml of mouse HGF in presence of 1 mM orthovanadate for 3 
minutes at 37°C, washed in PBS supplemented with 1 mM orthovanadate and phosStop 1X 
(Roche) and lysed in Extraction Buffer supplemented with 1 mM orthovanadate, 2X 
phosStop and Complete Mini protease inhibitor cocktail (Roche) for 20 minutes at 4°C. 
After clearance, samples were quantified and the same amount of proteins was used for 
MET and phospho-MET detection using a sandwich ELISA. Briefly, 96-well microtiter 
plates (MaxiSorp, Nunc) were coated with 1 μg/ml of anti-mouse MET antibody (AF527, 
R&D Systems) overnight at 4°C and then incubated for 2 hours at room temperature (RT) in 
blocking buffer (PBS, 0.1% Tween-20, 6% non-fat dry milk). The same amount of proteins 
per sample was diluted in blocking buffer and incubated for 2 hours at RT on the ELISA 
plate. After 6 washes in PBS 0.1% Tween-20, samples were incubated for 2 hours at RT 
with the mouse anti-MET (3D4, Invitrogen) or the mouse anti-phosphotyrosine (4G10, 
Merck Millipore) antibodies diluted 1:500 in blocking buffer, then washed 6 times in PBS 
0.1% Tween-20, and incubated with goat anti-mouse immunoglobulins conjugated to 
horseradish peroxidase (sc-2031, Santa Cruz Biotechnology) diluted 1:500 in blocking 
buffer for 2 hours at RT. Signals was developed by 15 minutes incubation with the 3,3′,5,5′-
tetramethylbenzidine (TMB) substrate solution (Promega). After stopping the reaction with 
H2SO4, absorbance was measured at 450 nm and corrected for 630 nm with a 
spectrophotometer.
Western blot
To assess MET deletion, BM cells, neutrophils, peritoneal macrophages, monocytes (all 
cultured overnight in TCM) or endothelial cells were lysed in hot Laemmli buffer (2.5% 
SDS, 25% Tris-HCl pH 6.8) for 10 minutes at 96°C, sonicated, cleared and quantified. 
Alternatively, 2×106 bone marrow derived neutrophils from WT mice were stimulated with 
TCM, CCM, 100 ng/ml of murine TNF-α (or mock medium 0% FBS or 10% FBS as 
control) for 20 hours at 37°C. For the co-culture with HUVEC, a monolayer of HUVEC was 
stimulated for 4 hours with 5 ng/ml IL-1α at 37°C, and washed before neutrophil seeding. 
After 20 hours of stimulation, neutrophils were collected using Cell Dissociation Buffer 
Enzyme Free PBS-Based (Gibco). Cells were washed in PBS, lysed in 15 μl of a protease 
inhibitor mixture and incubated for 15 minutes on ice. The protease inhibitor mixture was 
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obtained by dissolving one tablet of Complete Mini protease inhibitor mixture (Roche) in 5 
ml of PBS with 2 mM diisopropyl fluorophosphate (DFP; Acros Organics, Morris Plains, 
NJ). After addition of an equal amount of 2x SDS sample buffer supplemented with 4% 2-
mercaptoethanol, the lysates were boiled for 15 minutes and kept at −80°C until use. NF-κB 
inhibition was achieved by pre-treating 7×106 neutrophils with 10 μM 6-amino-4-(4-
phenoxyphenylethylamino) quinazoline (Calbiochem) for 1 hour at 37°C; cells were then 
stimulated with murine TNF-α (100 ng/ml) for 5 hours before lysis. Human MET was 
assessed by stimulating 3×107 blood neutrophils isolated from the blood of healthy 
volunteers with A549-CCM, 100 ng/ml human TNF-α, 50 ng/ml LPS (or mock medium 
10% FBS as control) for 20 hours. Cells were incubated with 2.7 mM DFP for 15 minutes at 
4°C, collected and washed in PBS supplemented with 2.7 mM DFP and Complete Mini 
protease inhibitor 1X, and lysed in hot Laemmli buffer at 96°C for 10 minutes. Cell lysates 
were sonicated, cleared and quantified. 6x loading buffer was added before loading on the 
gel. The following primary antibodies were used: mouse anti-mouse Met (3D4, Invitrogen), 
mouse anti-mouse β-actin (I-19, Santa Cruz), mouse anti-vinculin (hVIN-1, Sigma), rabbit 
anti-human Met (D1C2, Cell Signaling), HRP-conjugated anti-beta-tubulin (Abcam). The 
following secondary antibodies were used: HRP-conjugated goat anti-mouse and HRP-
conjugated goat anti-rabbit (Santa Cruz). Signal was visualized by Enhanced 
Chemiluminescent Reagents (ECL, Invitrogen) or West Femto by Thermo Scientific 
according to the manufacturer’s instructions.
Adhesion assay
4×104 HUVEC were seeded in M199 20% FBS in a 96-multiwell plate, previously coated 
with 0.1% gelatin. After 12 hours, HUVEC were stimulated with 5 ng/ml IL-1α in DMEM 
10% FBS at 37°C. After 4 hours the endothelial monolayer was thoroughly washed and 
2.5×105 WBC isolated indistinctly from Tie2;Metwt/wt and Tie2;Metlox/lox mice or from 
WT→WT and KO→WT transplanted mice, were seeded on top of it, with or without 
murine HGF (50 ng/ml). After 15 minutes non-adherent cells were washed out whereas 
adherent cells were detached by using a Cell Dissociation Buffer Enzyme Free PBS-Based 
(Gibco). Cells were stained for Ly6G (clone 1A8), washed and resuspended in PBS-BSA 
0.1% with unlabelled counting beads (BD Bioscience) and quantified by FACS Canto II 
(BD Bioscience).
Transmigration and migration assay
For the transmigration assay, 2×105 HUVEC were seeded on 3 μm polycarbonate membrane 
(Transwell; Costar) previously coated with 0.1% gelatin in M199 20% FBS. After 12 hours, 
HUVEC were stimulated for 4 hours at 37°C in DMEM 10% FBS with 5 ng/ml IL-1α and 
then washed. 5×105 WBC isolated indistinctly from Tie2;Metwt/wt and Tie2;Metlox/lox mice 
or from WT→WT and KO→WT transplanted mice were seeded on top of the endothelial 
monolayer, while mock medium, TCM (with or without 3 μg/ml anti-HGF antibody 
AF-2207, R&D18,31) or 50 ng/ml murine HGF was added in the bottom. After 2 hours at 
37°C, transmigrated cells were collected from the bottom chambers and from the lower side 
of the filter with cold PBS 0.5% EDTA. Cells were stained and Ly6G+ cells quantified as 
above. In the migration assays WBC were seeded directly on top of 3 μm polycarbonate 
porous membranes.
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Nitric oxide measurement by FACS
Neutrophils isolated from the blood of WT or KO LLC-tumour bearing mice were co-
cultured for 4 hours with LLC shMet, washed and resuspended in 20 mM Hepes-PBS, and 
incubated for 10 minutes with 5μM DAF-FM diacetate (Molecular probes) in absence or 
presence of mouse HGF (100 ng/ml) at 37°C. Cells were then washed and analysed by 
FACS.
Cytotoxicity assay
LLC shMet or T241 shMet were transduced with a luciferase-expressing lentiviral vector 
(EX-hLUC-Lv114 from GeneCopoeia); 104 cells were then seeded in DMEM 10% FBS in a 
96-multiwell plate. After 4 hours, 0.2×106 neutrophils purified from the blood of tumour 
bearing mice or directly from the tumours themselves, were co-cultured with the cancer cells 
in DMEM 2% FBS for 4 hours at 37°C, with or without 100 ng/ml mouse HGF or 1 mM L-
NMMA (Sigma). After washing, adherent cells were lysate in 0.2% Triton, 1 mM DTT. 
Luciferase signal was revealed with a microplate luminometer. The use of shMet was 
thought to prevent any possible confounding activity of MET on cancer cell survival and 
thus to restrict the effect of HGF to neutrophils only.
Histology and immunostainings
To obtain serial 7-μm-thick sections, tissue samples were immediately frozen in OCT 
compound or fixed in 2% PFA overnight at 4°C, dehydrated and embedded in paraffin. 
Paraffin slides were firstly rehydrated to further proceed with antigen retrieval in citrate 
solution (DAKO). Cryosections were thawed in water and fixed in 100% methanol. If 
necessary, 0.3% H2O2 was added to methanol to block endogenous peroxidases. The 
sections were blocked with the appropriate serum (DAKO) and incubated overnight with the 
following antibodies: rat anti-CD45 (30F-11, BD Pharmingen), rat anti-Ly6G (1A8, BD 
Pharmingen) 1:100, rat anti-CD31 (MEC 13.3, BD Pharmingen) 1:200, rabbit anti-FITC 
(Serotec) 1:200, goat anti-phosphohistone H3 (Cell Signaling) 1:100, rat anti-F4/80 
(CI:A3-1, Serotec) 1:100, mouse anti-NK1.1-biotin (PK136, BD Pharmingen) 1:200, rat 
anti-CD45R (RA3-6B2, BD Pharmingen) 1:100, rat anti-CD4 (H129.9, BD Pharmingen) 
1:100, rat anti-CD8 (53-6.72, BioXCell) 1:100, hamster anti-CD11c biotin (N418, 
eBioscience) 1:100, mouse anti-3-nitrotyrosin (HM.11 Santa Cruz) 1:200. Appropriate 
secondary antibodies were used: Alexa488-or Alexa568-conjugated secondary antibodies 
(Molecular Probes) 1:200, HRP-labelled antibodies (DAKO) 1:100, Biotin-labelled 
antibodies (Jackson ImmunoResearch) 1:100. When necessary, Tyramide Signaling 
Amplification (Perkin Elmer, Life Sciences) was performed according to the manufacturer’s 
instructions. Whenever sections were stained in fluorescence, ProLong Gold mounting 
medium with DAPI (Invitrogen) was used. Otherwise, 3,3′-diaminobenzidine was used as 
detection method followed by Harris’ haematoxilin counterstaining, dehydration and 
mounting with DPX. Apoptotic cells were detected by the TUNEL method, using the 
AptoTag peroxidase in situ apoptosis detection kit (Millipore) according to the 
manufacturer’s instructions. For the double staining TUNEL and LY6G, TUNEL staining 
was performed as described above, followed by Ly6G staining by using the Vectastain ABC 
kit (Vector laboratories) according to the manufacturer’s instructions. Tumour necrosis and 
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lung metastasis were evaluated by H&E staining. Necrotic area was defined as the area 
including necrotic cancer cells, inflammatory cells and stromal cells, compared to the total 
area of the field. Necrotic cells display a more glassy homogeneous appearance in the 
cytoplasm with increased eosinophilia, while the nuclear changes are reflected by 
karyolysis, pyknosis, and karyorrhexis. Alternatively, the necrotic tissue was visualized by 
autofluorescence as previously described35. Microscopic analysis was done with an 
Olympus BX41 microscope and Cell Sense imaging software or a Zeiss Axioplan 
microscope with KS300 image analysis software. The morphometric analysis was performed 
by acquiring 4-6 fields per sections on 5 independent sections (at a distance of 40 μm in 
depth during sectioning) from the same biological tissue sample. The values in the graphs 
represent the average of the means of, at least, 5 samples and the standard error indicates the 
variability among the different samples.
Hypoxia assessment and tumour perfusion
Tumour hypoxia was detected by injection of 60 mg/kg pimonidazole into tumour-bearing 
mice 1 hour before tumours harvesting. To detect the formation of pimonidazole adducts, 
tumour cryosections were immunostained with Hypoxyprobe-1-Mab1 (Hypoxyprobe kit, 
Chemicon) following the manufacturer’s instructions. Perfused tumour vessels were counted 
on tumour cryosections from mice injected intravenously with 0.05 mg FITC-conjugated 
lectin (Lycopersicon esculentum; Vector Laboratories).
Tumour-derived nitric oxide production
LLC tumours were collected 8 days after injection, cut in pieces of about 5×5 mm, weighted 
and incubate at 37°C in 24-multiwell with 800 μl of DMEM. After 24 hours, the media was 
collected, centrifuged to remove cell debris, and NO levels were measured using the Griess 
reagent system kit (Promega).
Statistics
Data entry and all analyses were performed in a blinded fashion. All statistical analyses were 
performed using GraphPad Prism software. Statistical significance was calculated by two-
tailed unpaired t-test on two experimental conditions or two-way ANOVA when repeated 
measures were compared, with P<0.05 considered statistically significant. Data were tested 
for normality using the D’Agostino-Pearson omnibus test (for n>8) or the Kolmogorov-
Smirnov test (for n≤8) and variation within each experimental group was assessed. 
Detection of mathematical outliers was performed using the Grubbs’ test in GraphPad. 
Sample sizes for all experiments were chosen based on previous experiences. Independent 
experiments were pooled and analysed together whenever possible as detailed in figure 
legends. All graphs show mean values ± s.e.m..
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Extended Data
Extended Data Figure 1. Scheme illustrating the role of MET in neutrophils
During cancer or infections, the release of cytokines such as IL-1 at the inflammatory site 
will promote the expression of TNF-α on the endothelium and the surrounding tissue. When 
circulating neutrophils will encounter the activated endothelium, TNF-α will unleash NF-κB 
through the binding to TNFR1, which in turn will induce MET expression on neutrophil 
surface. HGF, also released and proteolytically activated at the site of inflammation, will 
bind to MET and stimulate the firm adhesion of neutrophils to the endothelium, likely via 
integrin engagement, and thus neutrophil diapedesis. Once extravasated, HGF/MET 
pathway will still function on neutrophils by reinforcing their cytotoxic response through the 
induction of iNOS and NO production, ultimately favouring a bactericidal and tumouricidal 
neutrophil phenotype.
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Extended Data Figure 2. Met deletion in immune cells, but not in EC, fosters tumour growth
a, MET expression in total bone marrow (BM) cells, endothelial cells (EC) and neutrophils 
harvested from Met floxed mice intercrossed with the Tie2:Cre deleter thus generating 
Tie2;Metlox/lox (KO) or Tie2;Metwt/wt (WT) mice. Western blots are representative of 3 
repetitions on independent biological replicates. Western blot images have been cropped for 
presentation. Full scan images are shown in Supplementary Figure 1. b-d, Quantification (b) 
and representative images of tumour sections’ TUNEL stainings (c,d) from subcutaneous 
endstage LLC tumours in WT→WT and KO→WT mice. Data combine 2 independent 
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experiments; total n=10 mice/condition. e, FACS quantification of AnnexinV+ 7AAD− early 
apoptotic tumour cells in WT→WT and KO→WT mice. Data combine 2 independent 
experiments; total n=8 mice/condition. f-j, Tumour necrosis quantification in WT→WT and 
KO→WT mice (f), assessed by histologic evaluation of H&E stained tumour sections (g,h) 
and by measurement of autofluorescent tumour areas (i,j); yellow dotted lines demarcate 
necrosis. Data combine 2 independent experiments; total n=10 mice/condition. k-m, 
Quantification (k) and representative images of tumour sections stained for the proliferation 
marker pHH3 (l,m) from subcutaneous endstage LLC tumours in WT→WT and KO→WT 
mice. Data combine 2 independent experiments; total n=10 mice/condition. n, FACS 
quantification of BrdU+ proliferating tumour cells in WT→WT and KO→WT mice. Data 
combine 2 independent experiments; total n=10 mice/condition. o-r, CD31+ vessel area (o), 
vessel density (p), lectin perfusion (q), and hypoxic (Pimo+) area (r) in LLC subcutaneous 
tumours from KO→WT mice (where the hematopoietic/immune system is knocked out for 
Met) or WT→KO mice (where EC only are knocked out for Met) compared to control 
WT→WT mice. Data in o-r combine 2 independent experiments; total n: WT→WT=12, 
KO→WT=8, WT→KO=8. s-u, Subcutaneous LLC tumour growth (s), weight (t) and lung 
metastases (u) in Tie2;Metlox/lox compared to Tie2;Metwt/wt mice. Data combine 2 
independent experiments; total n: Tie2;Metwt/wt=12, Tie2;Metlox/lox=10. v, Tumour growth 
in endothelial cell specific Met KO (WT→KO) and control (WT→WT) mice. Data combine 
2 independent experiments; total n=8/condition. *, P<0.05 versus WT→WT (b,e,f,k,n), 
versus Tie2;Metwt/wt (s-u). Scale bars: 50 μm (c,d,l,m), 100 μm (g-j). All graphs show mean 
± s.e.m.
Finisguerra et al. Page 18
Nature. Author manuscript; available in PMC 2015 December 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
Extended Data Figure 3. Circulating and tumour-infiltrating immune cells upon Met deletion
a-e, FACS analysis showing percentages of circulating monocytes (a), lymphocytes (b), 
neutrophils (c), eosinophils (d), and basophils (e) in tumour free or in LLC-tumour bearing 
WT→WT and KO→WT mice. Data combine 2 independent experiments; total n=8 mice/
condition. f, Quantification of LLC-tumour sections stained for the pan-leukocyte marker 
CD45, the macrophage marker F4/80, the NK marker NK1.1, the B lymphocyte marker 
CD45R, the T helper cell marker CD4, the cytotoxic T cell marker CD8 and the dendritic 
cell marker CD11c (with exclusion of F4/80+ area) in WT→WT and KO→WT mice. Data 
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combine 2 independent experiments; total n=8 mice/condition). g,h, FACS quantification 
for tumour-associated CD45+ leukocytes (g) or CD45+ IgE+ CD49b+ CD4− CD45R− 
basophils and CD45+ CD11b+ SiglecF+ Ly6Cmed F4/80low MHCII− eosinophils (h) in 
WT→WT and KO→WT mice. Data combine 2 independent experiments; total n=8 mice/
condition. i,j, FACS quantification (i) and gating strategy (j) for tumour-associated 
neutrophils selected from the main tumour cell population negative for 7AAD staining; 
tumour-associated neutrophils were then gated as CD11b and Ly6G double positive cells. 
Data combine 2 independent experiments; total n: WT→WT=11, KO→WT=10. k, Ly6G+ 
tumour infiltration at day 9, day 13, and day 19 after LLC subcutaneous tumour injection in 
WT→WT and KO→WT mice. Data combine 2 independent experiments; total n=8 mice/
condition. l, Morphometric quantification of leukocytes and macrophages on respectively 
CD45 and F480-stained lung sections from LLC tumour-bearing WT→WT or KO→WT 
mice. Data combine 2 independent experiments; total n=8 mice/condition. m, FACS 
quantification of CD11b+ Ly6G+ neutrophils and CD11b+ F4/80+ macrophages infiltrating 
metastatic lungs from LLC tumour-bearing WT→WT or KO→WT mice. Data combine 2 
independent experiments; total n=8 mice/condition. *, P<0.05 versus WT→WT (f,g,i,k-m); 
#, P<0.05 versus Tumour free (a-d). All graphs show mean ± s.e.m.
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Extended Data Figure 4. MET in neutrophils is required for their anti-tumour activity
a,b, Western blot analysis (a) and relative densitometric analysis (b) for MET expression in 
BM neutrophils and monocytes upon reconstitution of WT recipient mice by WT or KO 
HSPCs transduced in vitro with an empty vector (Mrp8:Empty) or a vector expressing Met 
under the neutrophil-specific promoter Mrp8 (Mrp8:Met); tubulin was used as loading 
control. Western blots are representative of 3 repetitions on independent biological samples 
where each sample is the pool of neutrophils or monocytes isolated from 3 mice. 
Densitometric analysis has been performed on these 3 Western blots. c, FACS analysis for 
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GFP in circulating Ly6G+ neutrophils or CD115+ monocytes, harvested from the neutrophil-
specific Mrp8:Cre line carrying separate expression of GFP because of an Internal 
Ribosome Entry Site (IRES) downstream the Mrp8-driven Cre gene. Data combine 2 
independent experiments; total n=10 mice/condition. d, MET expression in neutrophils, 
monocytes, and macrophages harvested from Mrp8;Metwt/wt or Mrp8;Metlox/lox mice. 
Western blots are representative of 3 repetitions on independent biological replicates. e, 
FACS analysis for CD11b+ Ly6G+ neutrophils in subcutaneous LLC tumours from 
Mrp8;Metwt/wt or Mrp8;Metlox/lox. Data combine 2 independent experiments; total n: 
Mrp8;Metwt/wt=10, Mrp8;Metlox/lox=11. Western blot images in (a,d) have been cropped for 
presentation. Full scan images are shown in Supplementary Figure 1. *, P<0.05 versus 
Mrp8:Empty WT→WT (b), versus Mrp8;Metwt/wt (e); #, P<0.05 versus Mrp8:Empty 
WT→WT; $, P<0.05 versus Mrp8:Empty KO→WT. All graphs show mean ± s.e.m.
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Extended Data Figure 5. Pharmacologic and genetic inhibition of MET prevents the recruitment 
of anti-tumoural neutrophils to several neoplastic tissues and inflammatory sites
a, Tumour weight of subcutaneous B16F10 melanomas in WT→WT and KO→WT mice. 
Data combine 2 independent experiments; total n: WT→WT=8, KO→WT=9. b,c, Total 
tumour weight (b) and metastatic index (c) in MMTV-PyMT mice reconstituted with WT or 
Met KO BM cells before tumour appearance (WT→PyMT and KO→PyMT mice, 
respectively). Data combine 3 independent experiments; total n: WT→PyMT=13, 
KO→PyMT=16. d,e, FACS quantification for CD11b+ Ly6G+ neutrophils in T241 tumours 
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harvested from WT→WT or KO→WT mice (d) or in in breast tumours spontaneously 
grown in WT→PyMT and KO→PyMT mice (e). Data combine 2 independent experiments; 
total n=10 mice/condition (d) or total n=8 mice/condition (e). f-i, Length measurement (f) 
and representative image (g) of the colon, as well as quantification of neutrophils (h) and 
macrophages (i) on bowel sections, from WT→WT and KO→WT mice upon induction of 
chronic colitis compared to healthy control. Data combine 2 independent experiments; total 
n: healthy=5, WT→WT=12, KO→WT=15. j,k, Tumour weight (j) and metastatic 
mesenteric lymph nodes (k) 12 days after orthotopic injection of pancreatic Panc02 cancer 
cells in WT→WT and KO→WT mice. Data combine 2 independent experiments; total 
n=12/condition. l, Histological quantification of Ly6G+ infiltrates in Panc02 pancreatic 
tumours harvested from WT→WT and KO→WT mice. Data combine 2 independent 
experiments; total n=12 mice/condition. m, Quantification of plasma HGF in tumour (TM)-
free mice, in subcutaneous LLC or orthotopic Panc02 tumour-bearing mice. Data combine 2 
independent experiments; total n: TM free=10, LLC=10, Panc02=8 biological replicates. n, 
Quantification of HGF in subcutaneous LLC or orthotopic Panc02 tumours. Data combine 2 
independent experiments; total n: LLC=10, Panc02=8 biological replicates. o,p, 
Quantification of HGF in plasma (o) or in subcutaneous LLC tumours (p) from tumour-
bearing WT→WT and KO→WT mice. Data are representative of 2 independent 
experiments using 5 mice/condition per experiment. q, Quantification of Ly6G+ area on 
sections from B16F10 melanomas grown in C57BL/6 WT mice, daily treated with 
PF-04217903, INCB28060, JNJ-38877605, or vehicle as control. Data combine 2 
independent experiments; total n: vehicle=14, PF-04217903=9, INCB28060=6, 
JNJ-38877605=4. r, Western blot analysis for MET in B16F10 melanoma cells after 
transduction with a lentiviral vector encoding scramble or mouse shMet under a constitutive 
promoter; vinculin was used as loading control. Western blot is representative of 3 
independent repetitions. Western blot images have been cropped for presentation. Full scan 
images are shown in Supplementary Figure 1. *, P<0.05 versus WT→WT (a,d,h), versus 
WT→PyMT (b,e), versus LLC (m,n), versus Vehicle (q); #, P<0.05 versus Healthy (f,h,i), 
versus TM free (m). Scale bar: 10 mm (g). All graphs show mean ± s.e.m.
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Extended Data Figure 6. HGF is required for MET activation upon induction by TNF-α
a, Gating strategy related to Fig. 3b to quantify MET expression in blood neutrophils from 
LLC-tumour (TM)-bearing mice and in TANs, where live cells were first gated as CD11b 
positive cells; this population was finally gated for Ly6G and MET in order to identify 
MET-expressing Ly6G+ neutrophils. b,c, qRT-PCR for MET in mouse (b) and human (c) 
neutrophils after LPS or TNF-α stimulation. Data are representative of 3 independent 
experiments using 4 biological replicates/condition per experiment. d,e, qRT-PCR for MET 
expression in mouse (b) or human (c) neutrophils cultured in normoxia (21% O2) or hypoxia 
Finisguerra et al. Page 25
Nature. Author manuscript; available in PMC 2015 December 18.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
(1% O2). Data combine 2 independent experiments; total n=8 biological replicates/
condition. f,g, ELISA for total MET (f) and phospho-MET (g) from mouse neutrophils 
stimulated for 3 minutes with mock medium or HGF after an overnight incubation with or 
without TNF-α. Data combine 3 independent experiments; total n=6 biological replicates/
condition. h, HGF release by neutrophils stimulated with mock medium or TNF-α after 20 
hours in culture. Data combine 2 independent experiments; total n=6 biological replicates/
condition. i, qRT-PCR for TNFA in HUVEC upon stimulation with IL-1α compared to 
mock medium. Data combine 2 independent experiments; total n=4 biological replicates/
condition. j, qRT-PCR for Met in mouse neutrophils co-cultured with HUVEC/NS or 
HUVEC/IL transduced with shTNFA or scramble as control. Data are representative of 3 
independent experiments where 3 different shRNA sequences were used; total n=4 
biological replicates/condition per experiment. k,l, qRT-PCR for Met in WT, TNFR1 KO, 
TNRF2 KO neutrophils upon co-culture with HUVEC/NS or HUVEC/IL (k), or after 
stimulation with conditioned medium (TCM) from LLC tumours (l). Data are representative 
of 2 independent experiments using 4 biological replicates/condition per experiment. m, 
qRT-PCR for MET in human neutrophils stimulated with A549-CCM in presence or absence 
of Enbrel or human IgG as control. Data are representative of 2 independent experiments 
using 4 biological replicates/condition per experiment. *, P<0.05 versus Mock (b,c,i), versus 
TNF-α alone (g), versus HUVEC/NS (j), versus WT (k,l), versus A549-CCM (m); #, 
P<0.05 versus untreated or HGF alone (f,g), versus HUVEC/NS (k), versus Mock (l,m). 
Graph shows mean ± s.e.m.
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Extended Data Figure 7. Met deletion in neutrophils does not affect apoptosis
a,b, Gating strategy of apoptotic WT (a) and Met KO (b) neutrophils in LLC tumours where 
single cells suspensions were firstly gated for physical parameters and then for CD11b and 
Ly6G in order to identify neutrophils as double positive cells; this population was finally 
gated for AnnexinV and 7AAD: AnnexinV+ 7AAD− cells display early apoptotic 
neutrophils whereas AnnexinV+ 7AAD+ cells display late apoptotic neutrophils. c, 
Quantification of apoptotic WT and Met KO tumour-associated neutrophils measured by 
FACS. Data combine 2 independent experiments; total n=7 mice/condition. d, 
Quantification of apoptotic WT and Met KO neutrophils on LLC tumour sections by 
immunohistochemistry. Data combine 2 independent experiments; total n: WT→WT=7, 
KO→WT=6. e, FACS analysis for AnnexinV and 7AAD of WT or KO neutrophils 
incubated for 10 hours in presence or absence of LPS and HGF, alone or in combination. 
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Data combine 2 independent experiments; total n=6 biological replicates/condition. #, 
P<0.05 versus untreated or HGF alone. Graph shows mean ± s.e.m.
Extended Data Figure 8. MET affects neither neutrophil basal migration nor polarization but it 
is required for neutrophil recruitment and cytotoxicity
a, Quantification of Ly6G staining in ear-sections upon phorbol ester (TPA)-induced 
cutaneous rash in Mrp8;Metwt/wt and Mrp8;Metlox/lox mice. Data combine 2 independent 
experiments; total n=8 mice/condition. b, FACS analysis on peritoneal lavages for Ly6G+ 
neutrophils or F4/80+ macrophages in Mrp8;Metwt/wt and Mrp8;Metlox/lox mice 4 hours after 
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intra-peritoneal injection of sterile zymosan A. Data are representative of 2 independent 
experiments using 5 mice/condition per experiment. c,d, Quantification of F4/80 (c) and 
CD3 (d) stainings in ear-sections at baseline and upon TPA-induced cutaneous rash. Data 
combine 2 independent experiments; total n: WT→WT CTRL=22, KO→WT CTRL=15, 
WT→WT TPA=23, KO→WT CTRL=15 (c) or total n=8 mice/condition (d). e, FACS 
quantification of Mrp8;Metwt/wt and Mrp8;Metlox/lox neutrophils recruited into subcutaneous 
air pouches in response to HGF, CXCL1 or PBS. Data combine 2 independent experiments; 
total n=6 mice/condition. f, FACS quantification of WT neutrophil adhesion to quiescent 
HUVEC (HUVEC/NS) or activated HUVEC (HUVEC/IL) in presence or absence of HGF. 
Data are representative of 2 independent experiments using 4 biological replicates/condition 
per experiment. g,h, FACS quantification of WT and Met KO neutrophils migrated through 
a bare porous filter (i.e., in absence of HUVEC) towards HGF (g) or tumour conditioned 
medium (TCM) (h). Data are representative of 2 independent experiments using 3 biological 
replicates/condition per experiment. i, Gene expression profile for N1 and N2 markers in 
neutrophils sorted from LLC tumours grown in WT→WT or KO→WT mice. Data are 
representative of 3 independent experiments using 4 mice/condition per experiment. j, 
Cytotoxicity of WT and KO tumour-associated neutrophils against T241 cells in absence or 
presence of the NO synthase inhibitor L-NMMA. Data are representative of 3 independent 
experiments using 3 biological replicates/condition per experiment. k, FACS quantification 
of DAF-FM-positive circulating neutrophils after co-culture with LLC cancer cells as a 
readout of NO production in absence or presence of HGF. Data are representative of 4 
independent experiments using 3 biological replicates/condition per experiment. l, 
Quantification of LLC cancer cell killing by WT and KO neutrophils (isolated from the 
blood of tumour-bearing mice), stimulated with HGF alone or in presence of L-NMMA. 
Data are representative of 2 independent experiments using n=12 biological replicates/
condition per experiment. m, Blood neutrophils in WT→WT and KO→WT mice treated 
with neutrophil-depleting Ly6G antibody or rat IgG as control. Data combine 2 independent 
experiments; total n=16/condition. *, P<0.05 versus Mrp8;Metwt/wt (a,b), versus 
Mrp8;Metwt/wt + HGF (e), versus HUVEC/NS (f), versus WT→WT untreated (j), versus 
WT→WT + HGF (k,l); #, P<0.05 versus CTRL (c,d), versus PBS (e), versus Mock (f,h), 
versus WT→WT untreated (j-l), versus IgG (m); $, P<0.05 versus WT→WT + HGF (m). 
All graphs show mean ± s.e.m.
Extended Data Table 1
Blood count in Tie2;Metwt/wt or Tie2;Metlox/lox tumour 
free mice
The values show the hematological parameters (mean ± s.e.m.) in tumour free Tie2;Metwt/wt 
and Tie2;Metlox/lox mice. Data combine 2 independent experiments; total n=10/condition. 
Abbreviations: white blood cell (WBC), neutrophil (NEU), lymphocyte (LYM), monocyte 
(MON), eosinophil (EOS), basophil (BAS), red blood cell (RBC), hematocrit (HCT), mean 
cell hemoglobin concentration (MCHC), platelet (PLT).
Tumour free Tie2;Metwt/wt Tie2;Metlox/lox
WBC (k/μl) 5.68±1.44 5.55±1.29
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Tumour free Tie2;Metwt/wt Tie2;Metlox/lox
NEU (%) 23.03±5.45 29.67±7.88
LYM (%) 69.72±6.46 72.03±4.89
MON (%) 1.24±0.37 2.86±1.15
EOS (%) 0.12±0.05 0.17±0.12
BAS (%) 3.38±1.32 4.47±2.1
RBC (M/μL) 5.21±1.91 4.89±1.52
HCT (%) 71.3±3.43 60.2±13.38
MCHC (g/dl) 15.83±2.65 18.3±0.26
PLT (K/μL) 439.73±26.64 508±55.79
Extended Data Table 2
Blood count in WT→WT and KO→WT tumour free or 
tumour bearing mice
The values show the hematological parameters (mean ± s.e.m.) in tumour free or in LLC-
tumour bearing (21 days) WT→WT and KO→WT chimeric mice. Data combine 2 
independent experiments; total n=10/condition. Abbreviations: white blood cell (WBC), 
neutrophil (NEU), lymphocyte (LYM), monocyte (MON), eosinophil (EOS), basophil 
(BAS), red blood cell (RBC), hematocrit (HCT), mean cell hemoglobin concentration 
(MCHC), platelet (PLT).
Tumour free WT→WT KO→WT
WBC (k/μl) 10.03±2.05 8.66±0.93
NEU (%) 9.18±2.1 10.3±3.07
LYM (%) 85.2±2.91 83.94±3.46
MON (%) 1.41±0.48 1.3±0.4
EOS (%) 0.44±0.17 0.25±0.05
BAS (%) 3.77±0.68 4.21±0.18
RBC (M/μL) 8.21±0.54 9.3±0.21
HCT (%) 59.86±3.52 70.16±1.67
MCHC (g/dl) 18.63±0.61 13.4±0.16
PLT (K/μL) 589.26±134.65 758.4±50.63
Tumor bearing WT→WT KO→WT
WBC (k/μl) 7.97±0.63 9.12±1.22
NEU (%) 44.3±0.37 53.71±7.23
LYM (%) 27.29±8.33 33.96±2.52
MON (%) 1.79±0.75 1.9±0.64
EOS (%) 0.26±0.03 0.45±0.1
BAS (%) 1.94±0.53 1.84±0.57
RBC (M/μL) 5.5±0.54 6.83±0.46
HCT (%) 42.13±2.93 49.43±3.47
MCHC (g/dl) 18.27±0.5 19.24±0.05
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Tumour free WT→WT KO→WT
PLT (K/μL) 566.17±109.48 805.5±88.19
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. Met deficiency inhibits neutrophil recruitment to tumour and metastatic site
a-g, LLC tumour growth (a), weight (b), lung macrometastases (c), metastatic area (d), 
representative images of H&E-stained lung sections (e,f), metastatic index (g) in WT→WT 
and KO→WT chimeras. Data combine 3 independent experiments; total mice: 
WT→WT=23, KO→WT=26. h-m, Neutrophil quantification and representative images on 
Ly6G-stained LLC tumour sections (h-j) or on lung sections from tumour-free and tumour-
bearing mice (k) represented in (l,m). Data in (h) are representative of 4 independent 
experiments (6 mice/condition per experiment). Data in (k) combine 3 independent 
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experiments; total mice: Tumour-free=10/condition, Tumour-bearing=15/condition. n-q, 
LLC tumour growth (n), tumour weight (o), lung macrometastases (p), TAN quantification 
(q) in WT→WT and KO→WT control chimeras (Mrp8:Empty) or upon neutrophil-specific 
Met reconstitution (Mrp8:Met). Data combine 2 independent experiments; total mice=10/
condition. r-u, LLC tumour growth (r), tumour weight (s), lung macrometastases (t), TAN 
quantification (u) upon neutrophil-specific Met deletion (Mrp8;Metlox/lox) and controls 
(Mrp8;Metwt/wt). Data combine 2 independent experiments; total mice=13/condition. *, 
P<0.05. Scale bars: 100 μm (e,f), 50 μm (i,j,l,m). Graphs show mean ± s.e.m..
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Figure 2. Met deficiency in hematopoietic cells fosters progression of several tumour types
a-c, Growth of T241 fibrosarcomas (a), B16F10 melanomas (b), PyMT-driven breast 
tumours (c). Data in (a,b) combine 2 independent experiments; total mice=14/condition (a), 
8/condition (b). Data in (c) combine 3 independent experiments; total mice: 
WT→PyMT=13, KO→PyMT=16. d-g, Liver weight (d), nodules (e), and images (f,g) after 
H-RasG12V/c-Myc-driven HCC (n=4 mice/condition). h-j, Quantification (h) on H&E-
stained bowel sections (i,j) of AOM/DSS-induced colon adenomas (yellow arrowheads) or 
carcinomas (red arrowheads). Data combine 2 independent experiments; total mice=10/
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condition. k, Spontaneous lung metastases from B16F10 tumours or lung colonisation after 
B16F10 intravenous injection. Data combine 2 independent experiments; total mice=8/
condition. l, Lung macrometastases from PyMT tumours. Data combine 3 independent 
experiments; total mice: WT→PyMT=13, KO→PyMT=16. m, TAN quantification in T241, 
B16F10, PyMT, HCC, CRC tumour-tissues. Total mice: T241, CRC=10/condition, 
B16F10=8/condition, combining 2 experiments; WT→PyMT=13, KO→PyMT=16, 
combining 3 experiments; HCC=4/condition (1 experiment). n,o, B16F10 tumour growth 
(n), spontaneous metastases and lung colonisation (o) in Mrp8;Metwt/wt and Mrp8;Metlox/lox 
mice. Data combine 2 independent experiments; total mice: Mrp8;Metwt/wt=12, 
Mrp8;Metlox/lox=8. p, Liver nodules in Mrp8;Metwt/wt and Mrp8;Metlox/lox HCC-bearing 
mice. Total mice=7/condition. q, TAN quantification in B16F10 tumours (total mice=8/
condition) or HCC (total mice=7/condition). r-t, Tumour growth (r), weight (s) and TANs 
in Met-silenced (shMet) and scramble B16F10 tumours after PF-04217903 or vehicle 
treatment. Data combine 2 independent experiments (total mice=11/condition for scramble, 
14/condition for shMet). *, P<0.05. Scale bars: 200 μm (i,j), 0.5 cm (f,g). Graphs show 
mean ± s.e.m..
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Figure 3. Met expression in neutrophils is induced by tumour-derived soluble factors
a-b, qRT-PCR (a) and FACS (b) analysis for MET in blood neutrophils from tumour (TM)-
free or LLC-tumour-bearing mice and in TANs. c, qRT-PCR for MET in human neutrophils 
from lung cancer versus healthy tissue. n=4 patients. d,e, MET expression by qRT-PCR (d) 
and Western blot (e) in circulating neutrophils from tumour-free mice after co-culture with 
unstimulated (HUVEC/NS) or IL-1α-pre-stimulated (HUVEC/IL) HUVEC, or after 
stimulation with TCM or CCM. f,g, qRT-PCR (f) or Western blot (g) for MET in circulating 
human neutrophils after stimulation with A549-CCM. h, Western blot for MET in mouse 
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and human neutrophils after LPS or TNF-α stimulation. i, qRT-PCR for Met in WT, TNFR1 
KO or TNFR2 KO neutrophils after TNF-α stimulation. j,k, qRT-PCR (j) and Western blot 
(k) for MET in mouse neutrophils after TNF-α stimulation with or without NF-κB inhibitor. 
l, qRT-PCR for Met in mouse neutrophils co-cultured with HUVEC/IL or stimulated with 
TCM in presence or absence of Enbrel. m,n, FACS for MET in TANs (m) and 
immunohistochemistry for Ly6G (n) in LLC tumours after Enbrel. Data combine 2 
independent experiments; total mice=5/condition. All data in (a,b,d,f,i,j,l) are representative 
of 2 independent experiments using 4 biological replicates/condition per experiment. All 
Western blots were repeated 3 times on independent biological replicates. Full Western blot 
images are shown in Supplementary Figure 1. Loading control in (e,h) displays tubulin or 
actin according to Supplementary Figure 1. *, P <0.05; #, P <0.05 versus Mock (i,l), versus 
untreated (j). Graphs show mean ± s.e.m..
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Figure 4. MET is required for neutrophil transendothelial migration and cytotoxicity
a-c, Neutrophils quantification (a) on TPA-painted ear skin (b,c). Data combine 2 
independent experiments; total mice=10/condition for vehicle, 14/condition for TPA. d, 
FACS analysis for Ly6G+ neutrophils or F4/80+ macrophages on peritoneal lavages after 
zymosan-induced peritonitis. Data are representative of 2 independent experiments using 4 
mice/condition per experiment. e, FACS analysis for neutrophil recruitment towards HGF or 
CXCL1 in air pouch assays. Data combine 3 independent experiments; total mice=10/
condition. f, Ly6G infiltration in LLC tumours or in TPA-painted ear skin after anti-HGF. 
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Data combine 2 independent experiments; total mice: IgG=11, anti-HGF=6. g-i, Neutrophil 
adhesion to HUVEC/IL (g) and transendothelial migration in response to HGF (h) or TCM 
with or without anti-HGF (i). Data in (g-i) are representative of 3 independent experiments 
using 3 biological replicates/condition per experiment. j,k, qRT-PCR for Nos2 in LLC-
tumour-associated neutrophils or macrophages (j) and tumour-derived NO production (k). l-
n, Quantification (l) and representative images (m,n) of 3NT and Ly6G-costained LLC 
tumour sections. Data in (j-n) combine 2 independent experiments; total mice=8/condition. 
o, TAN cytotoxicity against LLC cells with or without L-NMMA. Data are representative of 
4 independent experiments using 3 biological replicates/condition per experiment. p-r, LLC 
tumour growth (p), weight (q), TANs (r) following neutrophil-depleting anti-Ly6G 
treatment. Data combine 2 independent experiments; total mice=16/condition. *, P<0.05; #, 
P<0.05 versus PBS (e), versus Mock (g-i), versus WT→WT untreated (o). Scale bars: 100 
μm (b,c), 20 μm (m,n). Graphs show mean ± s.e.m..
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